**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

| | | |
|---|---|---|
| In re application of: Timo Kars van den Berg et al. | ) | Attorney Docket No. 080743235001 |
| Serial No.: 10/007,275 | ) | |
| Filed: October 26, 2001 | ) | |
| For: METHOD FOR INHIBITING CELL FUNCTIONING FOR USE IN ANTI-INFLAMMATORY AND ANTI-TUMOR THERAPIES | ) | |
| Examiner: Yaen, Christopher H. | ) | |
| Group Art Unit: 1642 | ) | |
| Confirmation No.: 5284 | ) | |



AMENDMENTS TO THE CLAIMS

A3

Claim 1 (Currently Amended) A method for inhibiting cell functioning for use in anti-inflammatory and anti-tumor therapies in the body of a warm-blooded living being, which comprises administering to said being a drug comprising, in a quantity effective for said therapies, a substance that specifically recognizes the extracellular domain of SIRP (anti-SIRP substance) and that inhibits the functioning of microphages by suppressing their activation by a factor of at least 10 as measured by each of the following microphage activity tests: (i) the production of nitric oxide (NO), (ii) the production of reactive oxygen species, and (iii) the production of tumor necrosis factor-alpha (TNF-α)~~pathologic myeloid cells~~.

Claim 2 (Cancelled)

Claim 3 (Currently Amended) The method as claimed in claim 1, wherein said substance inhibits the functioning of macrophases ~~pathologic myeloid cells by suppressing the~~

~~division of macrophage tumor cell lines by a factor of at least 10~~ as measured by the macrophage division test.

Claim 4 (Currently Amended) The method as claimed in claim 1 including the step of ~~for~~ treating pathologies selected from inflammations caused by autoimmune diseases or by allergies, and myeloid leukemia.

Claim 5 (Currently Amended) The method as claimed in claim 1, wherein said substance inhibits the functioning of macrophages by temporally suppressing their phagocytosis as measured by a ~~the~~ macrophage phagocytosis test.

A3 conclude

Claim 6 (Currently Amended) The method as claimed in claim 5 including the step of ~~for~~ improving the efficacy of gene-targeted therapies.

Claim 7 (Original) The method as claimed in claim 1, characterized in that said anti-SIRP substance is selected from the group consisting of Fab-fragments of monoclonal antibodies and (bio)chemically modified products of such fragments wherein the intended anti-SIRP activity has been maintained.

Claim 8 (Original) The method as claimed in claim 7, wherein said anti-SIRP substance is a Fab-fragment of monoclonal antibody ED9 or ED17, or said modified product thereof.

Claim 9 (Cancelled)

Claim 10 (Cancelled)

Claim 11 (Withdrawn)

Claim 12 (Withdrawn)

Claim 13 (Withdrawn)

Claim 14 (Withdrawn)